Journal article
A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation
Biology of blood and marrow transplantation, Vol.13(10), pp.1201-1206
2007
DOI: 10.1016/j.bbmt.2007.06.012
PMID: 17889357
Abstract
Hydroxychloroquine (HCQ) is an immunosuppressive lysosomotropic amine that has activity against graft-versus-host disease (GVHD). In a single-institution phase III trial, 95 recipients of allogeneic peripheral blood stem cell (PBSC) transplantation were randomized to receive, in a double-blind fashion, and in addition to prophylactic cyclosporine A (CSA), HCQ, or placebo starting 21 days pretransplant and continued until day +365. HCQ was very well tolerated and not associated with side effects. Overall, the incidence of acute GVHD (aGVHD) was 59% in both arms, and severe aGVHD occurred in 11% (HCQ) and 14% (placebo) (
P = .76). Sixty percent and 78% of patients developed chronic GVHD (cGVHD) in the HCQ and the placebo arms, respectively (
P = .15). With a median follow-up of 18 months, relapse-free and overall survivals (OS) were comparable in both groups. In summary, in this randomized trial, the addition of HCQ to single-agent CSA had no effects on aGVHD or cGVHD or survival.
Details
- Title: Subtitle
- A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation
- Creators
- Thomas Fong - Division of Oncology, Section of Leukemia & Bone Marrow Transplantation, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MissouriKathryn Trinkaus - Division of Biostatistics, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MissouriDouglas Adkins - Division of Oncology, Section of Leukemia & Bone Marrow Transplantation, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MissouriRavi Vij - Division of Oncology, Section of Leukemia & Bone Marrow Transplantation, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MissouriSteven M Devine - Division of Oncology, Section of Leukemia & Bone Marrow Transplantation, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MissouriMichael Tomasson - Division of Oncology, Section of Leukemia & Bone Marrow Transplantation, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MissouriLawrence T Goodnough - Division of Oncology, Section of Leukemia & Bone Marrow Transplantation, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MissouriSandra Lopez - Division of Oncology, Section of Leukemia & Bone Marrow Transplantation, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MissouriTimothy Graubert - Division of Oncology, Section of Leukemia & Bone Marrow Transplantation, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MissouriShalini Shenoy - Department of Pediatrics, Division of Pediatric Hematology-Oncology, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MissouriJohn F DiPersio - Division of Oncology, Section of Leukemia & Bone Marrow Transplantation, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MissouriHanna J Khoury - Division of Oncology, Section of Leukemia & Bone Marrow Transplantation, Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri
- Resource Type
- Journal article
- Publication Details
- Biology of blood and marrow transplantation, Vol.13(10), pp.1201-1206
- DOI
- 10.1016/j.bbmt.2007.06.012
- PMID
- 17889357
- NLM abbreviation
- Biol Blood Marrow Transplant
- ISSN
- 1083-8791
- eISSN
- 1523-6536
- Publisher
- Elsevier Inc
- Language
- English
- Date published
- 2007
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984094514102771
Metrics
31 Record Views